Business Context and Reporting Period
OrthoPediatrics Corp., an emerging growth company incorporated in Delaware, filed this Form 8-K on October 19, 2018. The report discloses a regulatory milestone regarding the Company's surgical systems for pediatric orthopedic care.
Key Financial Metrics
This filing is a current report regarding a regulatory event and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The primary material event reported is the receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for the RESPONSE 4.5/5.0mm System. This system is designed to treat smaller stature younger patients with complex scoliosis. It marks the Company's 26th surgical system.
Guidance, Outlook, and Management Commentary
- Launch Timeline: The Company expects to launch the RESPONSE 4.5/5.0mm System in the fourth quarter of 2018.
- Regulatory Status: The clearance was announced via a press release issued on October 19, 2018.
- Disclosure Note: The press release and this Item 7.01 are not deemed "filed" for purposes of Section 18 of the Exchange Act and are not incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Verify the commercial launch date of the RESPONSE 4.5/5.0mm System in Q4 2018.
- Review the full text of the press release (Exhibit 99.1) for specific indications and limitations of the cleared system.
- Monitor future filings for financial impact analysis related to the new product launch.